Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Fate Therapeutics Inc as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 272
- +13 vs. Q1 2021
- Shares held
- 94.4M
- +1.14M (+1.2%) vs. Q1 2021
- Total value
- $8.20B
- +$501.0M (+6.5%) vs. Q1 2021
- New holders
- 50
- 101 more added
- Sold out
- 37
- 77 more reduced
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FATE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 156 | $193.2M |
| Q1 2026 | 158 | $88.9M |
| Q4 2025 | 146 | $70.9M |
| Q3 2025 | 143 | $101.6M |
| Q2 2025 | 139 | $88.9M |
| Q1 2025 | 132 | $76.3M |
| Q4 2024 | 159 | $166.5M |
| Q3 2024 | 164 | $401.6M |
| Q2 2024 | 182 | $401.1M |
| Q1 2024 | 167 | $904.0M |
| Q4 2023 | 159 | $357.2M |
| Q3 2023 | 171 | $202.9M |
| Q2 2023 | 188 | $519.6M |
| Q1 2023 | 182 | $641.6M |
| Q4 2022 | 228 | $1.07B |
| Q3 2022 | 239 | $2.41B |
| Q2 2022 | 233 | $2.70B |
| Q1 2022 | 249 | $3.92B |
| Q4 2021 | 250 | $5.66B |
| Q3 2021 | 266 | $5.67B |
| Q2 2021 | 272 | $8.20B |
| Q1 2021 | 260 | $7.73B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Fate Therapeutics Inc; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ETF Managers Group, LLC | 0 | $0 | 0.00% | −2,263−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −822−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −265−100.0% | Sold out |
| Hanseatic Management Services Inc | 0 | $0 | 0.00% | −65−100.0% | Sold out |
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −63−100.0% | Sold out |
| Bellwether Advisors, LLC | 0 | $0 | 0.00% | −47−100.0% | Sold out |
| Manchester Financial Inc | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Meridian Wealth Partners, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Amundi Asset Management US, Inc. | – | – | – | – | Not filed |